Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Horizon Research Group LLC

Neither a doctor nor a teaching hospital

Research payments

$643,481

206 payments

Through program year 2025, Horizon Research Group LLC is reported as receiving $643,481 in research payments, across 206 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $4,925 1
2024 Research $40,576 3
2023 Research $85,172 55
2022 Research $226,251 15
2021 Research $116,584 38
2020 Research $94,005 16
2019 Research $75,967 78

Breakdown

Who paid Research payments · program years 2019–2025
  1. Boehringer Ingelheim Pharmaceuticals, Inc. $207,783 5 payments
  2. Otsuka Pharmaceutical Development & Commercialization, Inc. $167,845 3 payments
  3. AstraZeneca Pharmaceuticals LP $98,546 11 payments
  4. Vertex Pharmaceuticals Incorporated $83,442 6 payments
  5. Akebia Therapeutics Inc $66,933 171 payments
  6. Ardelyx, Inc. $8,440 6 payments
  7. GlaxoSmithKline, LLC. $7,853 2 payments
  8. AstraZeneca UK Limited $2,600 1 payment
  9. Boehringer Ingelheim International GmbH $39 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. Phase II dose finding PoCC in CKD $191,409 5 payments
  2. Phase 3B, Randomized, Open-Label, Sponsor-Blind, Active-Controlled Study Evaluating the Efficacy and Safety of Oral Vadadustat, Once Daily (QD) and Three Times Weekly (Tiw) for the Maintenance Treatment of Anemia in Hemodialysis Subjects Converting From Erythropoiesis-Stimulating Agents (Esas) $167,845 3 payments
  3. A Phase 2/3 Adaptive, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Subjects Aged 18 Years and Older With APOL1-mediated Proteinuric Kidney Disease $47,654 3 payments
  4. A Study of the Prevalance of Apolipoprotein L1 (APOL1) Alleles Among Individuals With Proteinuric Kidney Disease Who Are of Recent African Ancestry or Geographic Origin $35,788 3 payments
  5. A Phase 3 Randomized Double Blind Placebo Controlled Study Evaluating the Safety and Efficacy of Roxadustat AZD9941 for the Treatment of Anemia in Chronic Kidney Disease Patients not on Dialysis $30,744 1 payment
  6. NEUTRALIZE - Lokelma Metabolic Acidosis Study A double-blind randomized placebo-controlled parallel design multicenter phase IIIb study of Lokelmas effect on serum potassium and serum bicarbonate in patients with CKD hyperkalemia and metabolic acidosis of CKD $19,697 6 payments
  7. a phase 3,randomised,double blind,active controlled study to assess the efficacy,safety and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on chronic kidney disease ckd progression in participants with ckd and high blood pressure $19,425 2 payments
  8. Akb-6548-Ci-0014 $18,778 19 payments
  9. Phase II dose finding/PoCC in CKD $16,413 1 payment
  10. Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos) $15,680 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record